NCT07126782View on ClinicalTrials.gov

The Efficacy and Safety Assessment of Allogeneic γδ T Cells in Patients With MRD-positive AML After Allo-HSCT

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 20, 2025

Primary Completion Date

December 20, 2027

Study Completion Date

July 20, 2028

Conditions
AML (Acute Myelogenous Leukemia)AML
Interventions
BIOLOGICAL

Ex-vivo expanded allogeneic γδ T cells

Cells will be extracted from a healthy donor by apheresis, followed by ex-vivo expansion and activation. The ex-vivo expanded γδ T cells from donors will be adoptively transfused.

Trial Locations (1)

Unknown

RECRUITING

Institute of Hematology & Blood Diseases Hospital, Beijing

All Listed Sponsors
lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER